Department of Respiratory Medicine, Xiangya Hospital, Central South University, Changsha 410008, China.
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2022 Dec 28;47(12):1695-1703. doi: 10.11817/j.issn.1672-7347.2022.210596.
Coronavirus disease 2019 (COVID-19) in elderly and patients with chronic respiratory diseases (COPD) had a poor prognosis. COPD is one of the most common chronic respiratory diseases. We explore the epidemiological characteristics of patients with severe COVID-19 with COPD patients in order to provide medical evidence for the prevention and treatment of severe COVID-19.
We retrospectively analyzed the clinical baseline characteristics, treatment strategies, disease progression and prognosis of 557 severe COVID-19 patients admitted to the West Court of Union Hospital of Huazhong University of Science and Technology from January 29, 2020 to April 8, 2020.
A total of 465 patients with severe COVID-19 were enrolled in the study, including 248 (53.3%) males and 217 (46.7%) females. The median age of severe COVID-19 patients was 62.0 years, and 53 patients were complicated with COPD. Common symptoms at the onset included fever (78.5%), dry cough (67.1%), shortness of breath (47.3%) and fatigue (40.9%). Compared with non-COPD patients, patients with COPD had significantly lower levels of SpO2 in admission (90.0% vs 92.0%, P=0.014). In terms of laboratory examinations, patients with COPD had higher levels of C-reactive protein, interleukin-6, procalcitonin, total bilirubin, blood urea nitrogen, serum creatinine, lipoprotein (a), high-sensitivity troponin I, and D-dimer, while had lower levels of platelet counts, albumin and apolipoprotein AI. Severe COVID-19 patients with COPD had higher Sequential Organ Failure Assessment scores [3.0(2.0, 3.0) vs 2.0(2.0, 3.0), P=0.038] and CURB-65 score [1.0(1.0, 2.0) vs1.0(0.0, 1.0), P<0.001], and a higher proportion of progressing to critical illness (28.3% vs 10.0%, P<0.001) with more complications [e.g. septic shock (15.1% vs 6.1%, P=0.034)], had higher incidence rates of antibiotic therapies (90.6% vs 77.2%, P=0.025), non-invasive (11.3% vs 1.7%, P<0.001) and invasive mechanical ventilation (17.0% vs 8.3%, P=0.039), ICU admission (17.0% vs 7.5%, P=0.021) and death (15.1% vs 6.1%, P=0.016). Cox proportion hazard model was carried out, and the results showed that comorbid COPD was an independent risk factor for severe COVID-19 patients progressing to critical type, after adjusting for age and gender [adjusted hazard ratio (AHR)=2.38(1.30-4.37), P=0.005] and additionally adjusting for chronic kidney diseases, hypertension, coronary heart disease [AHR=2.63(1.45-4.77), P<0.001], or additionally adjusting for some statistically significant laboratory findings [AHR=2.10(1.13-3.89), P=0.018].
Severe COVID-19 patients with COPD have higher levels of disease severity, proportion of progression to critical illness and mortality rate. Individualized treatment strategies should be adopted to improve the prognosis of severe COVID-19 patients.
新冠肺炎(COVID-19)在老年患者和慢性呼吸系统疾病(COPD)患者中预后较差。COPD 是最常见的慢性呼吸系统疾病之一。我们探讨了严重 COVID-19 患者中合并 COPD 患者的流行病学特征,为严重 COVID-19 的防治提供医学证据。
我们回顾性分析了 2020 年 1 月 29 日至 2020 年 4 月 8 日期间华中科技大学同济医学院附属协和医院西院收治的 557 例严重 COVID-19 患者的临床基线特征、治疗策略、疾病进展和预后。
共纳入 465 例严重 COVID-19 患者,其中男性 248 例(53.3%),女性 217 例(46.7%)。严重 COVID-19 患者的中位年龄为 62.0 岁,53 例合并 COPD。常见的首发症状包括发热(78.5%)、干咳(67.1%)、呼吸急促(47.3%)和乏力(40.9%)。与非 COPD 患者相比,COPD 患者入院时 SpO2 水平明显较低(90.0%比 92.0%,P=0.014)。在实验室检查方面,COPD 患者的 C 反应蛋白、白细胞介素-6、降钙素原、总胆红素、血尿素氮、血肌酐、脂蛋白(a)、高敏肌钙蛋白 I 和 D-二聚体水平较高,血小板计数、白蛋白和载脂蛋白 AI 水平较低。合并 COPD 的严重 COVID-19 患者序贯器官衰竭评估(SOFA)评分较高[3.0(2.0,3.0)比 2.0(2.0,3.0),P=0.038]和 CURB-65 评分较高[1.0(1.0,2.0)比 1.0(0.0,1.0),P<0.001],进展为危重症的比例较高(28.3%比 10.0%,P<0.001),并发症较多[如感染性休克(15.1%比 6.1%,P=0.034)],抗生素治疗比例较高(90.6%比 77.2%,P=0.025),无创(11.3%比 1.7%,P<0.001)和有创机械通气(17.0%比 8.3%,P=0.039)、重症监护病房(ICU)入住率(17.0%比 7.5%,P=0.021)和死亡率(15.1%比 6.1%,P=0.016)较高。进行 Cox 比例风险模型分析,结果显示,在调整年龄和性别后,合并 COPD 是严重 COVID-19 患者进展为危重症的独立危险因素[调整后危险比(AHR)=2.38(1.30-4.37),P=0.005],并且在进一步调整慢性肾脏病、高血压、冠心病时[AHR=2.63(1.45-4.77),P<0.001],或进一步调整一些有统计学意义的实验室发现时[AHR=2.10(1.13-3.89),P=0.018]。
合并 COPD 的严重 COVID-19 患者疾病严重程度更高,进展为危重症和死亡率更高。应采用个体化治疗策略,以改善严重 COVID-19 患者的预后。